Question 1

What is ASFOTASE ALFA used for?

Accepted Answer

ASFOTASE ALFA (brand name STRENSIQ) is a Other indicated for See full prescribing information.

Question 2

How does ASFOTASE ALFA work?

Accepted Answer

ASFOTASE ALFA works through the following mechanism: 12.1 Mechanism of Action HPP is caused by a deficiency in TNSALP enzyme activity, which leads to elevations in several TNSALP substrates, including inorganic pyrophosphate (PPi). TNSALP is a metallo-enzyme that catalyzes the hydrolysis of phosphomonoesters with release of inorganic phosphate and alcohol. Elevated extracellular levels of PPi block hydroxyapatite crystal growth which inhibits bone mineralization and causes an accumulation of unmineralized bone matrix which manifests as rickets and bone deformation in infants and children and as osteomalacia (softening of bones) once growth plates close, along with muscle weakness. Replacement of the TNSALP enzyme upon STRENSIQ treatment reduces the enzyme substrate levels..

Question 3

What are the most common side effects of ASFOTASE ALFA?

Accepted Answer

Reported side effects vary by individual. The side-effects section on this page lists the events most frequently reported to FDA FAERS for ASFOTASE ALFA. FAERS is voluntary reporting, so it reflects what was reported, not absolute incidence.

Question 4

Is ASFOTASE ALFA the same as STRENSIQ?

Accepted Answer

STRENSIQ is a brand name for ASFOTASE ALFA. They share the same active ingredient and FDA-approved indications. Biosimilars and authorised generics may differ in inactive ingredients such as buffers or preservatives.

ASFOTASE ALFA

Mechanism of Action

Indications

FDA Warnings

Known Side Effects

Community Discussions

Primary sources

Compare With

Formulations